Benzinga | Dec 3, 2021 04:53AM EST

AstraZeneca Announced Data From Destiny-Breast03 Will Reaffirm Efficacy Of Enhertu

AstraZeneca will underscore its ambition to redefine care with new data from across its portfolio of innovative medicines at the 2021 San Antonio Breast Cancer Symposium (SABCS) 7-10 December 2021.

Fourteen AstraZeneca medicines and potential new medicines from the pipeline will be featured across 33 abstracts showcasing the Company's leadership across different types and stages of breast cancer, including three oral presentations.

Breast cancer is now the most diagnosed cancer worldwide with an estimated 2.3 million people diagnosed in 2020.1

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "Continuing our year of breakthroughs in breast cancer, our data at SABCS will reinforce the practice-changing potential of Enhertu with new analyses from the DESTINY-Breast03 trial. Early data from the BEGONIA and TROPION-PanTumor01 trials demonstrate great promise in treating patients who have limited treatment options. These data build on our decades of experience in pioneering medicines to redefine care for patients."

Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: "Progress in breast cancer increasingly involves more personalised approaches to treating patients across subtypes and stages of disease, which is a key focus of our data at this year's SABCS. Our extensive knowledge of breast cancer disease biology and the patient experience fuel our ambition to deliver medicines that can truly revolutionise and reshape treatment for every type of breast cancer patient."

Transforming the treatment of advanced breast cancers with antibody drug conjugates (ADCs)An oral presentation will share further results from a range of patient subgroups from the DESTINY-Breast03 Phase III trial, including those with stable brain metastases and patients characterised by hormone receptor status, number of prior lines of therapy or status of visceral metastasis.

Results from DESTINY-Breast03 demonstrated superior progression-free survival (PFS) for Enhertu (trastuzumab deruxtecan) versus trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer previously treated with trastuzumab and a taxane.

In another oral presentation, updated results from the TROPION-PanTumor01 Phase I trial will continue to build promising evidence of the anti-tumour activity of datopotamab deruxtecan in patients with triple-negative breast cancer (TNBC).

Treating breast cancer early where there is more opportunity for cureNew data on patient quality of life from the OlympiA Phase III trial of Lynparza (olaparib) will be presented as an oral presentation.

These patient-reported outcomes data will provide compelling evidence that further supports Lynparza as a potential treatment option for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk HER2-negative early breast cancer.

The supplemental New Drug Application of Lynparza for this indication was recently granted Priority Review by the US Food and Drug Administration.

Changing the treatment landscape with next-generation medicines and novel combinationsA poster and spotlight poster discussion will share results from the BEGONIA Phase Ib/II trial testing Imfinzi (durvalumab) combinations in advanced/metastatic TNBC with data from arm 1 (Imfinzi plus paclitaxel), arm 2 (Imfinzi, paclitaxel and capivasertib) and arm 5 (Imfinzi, paclitaxel and oleclumab), which will further demonstrate the benefits of combining immune checkpoint inhibitors with other novel molecules.

Additionally, ongoing trials posters will share information about the ongoing SERENA-4 Phase III trial which evaluates our next-generation oral selective oestrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with CDK4/6 inhibitors in the 1st-line treatment of patients with oestrogen receptor (ER)-positive, HER2-negative advanced breast cancer, and the SERENA-6 Phase III trial of camizestrant with CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer with an ESR1 mutation.

A further ongoing trial poster will share information on the CAPItello-292 Phase III trial, evaluating the benefit of adding capivasertib (an AKT inhibitor) to the treatment regimen of Faslodex (fulvestrant) and palbociclib in patients with HR-positive, HER2-negative locally advanced, unresectable or metastatic breast cancer.

Enhertu and datopotamab deruxtecan are developed and commercialised in collaboration with Daiichi Sankyo worldwide, except in Japan where Daiichi Sankyo maintains exclusive rights. Lynparza is developed and commercialised in collaboration with MSD (Merck & Co., Inc. in the US and Canada).